Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Место риоцигуата в терапии легочной артериальной гипертензии и хронической тромбоэмболической легочной гипертензии
Место риоцигуата в терапии легочной артериальной гипертензии и хронической тромбоэмболической легочной гипертензии
Платонов Д.Ю., Яковлева О.Э., Бельдиев C.Н. и др. Место риоцигуата в терапии легочной артериальной гипертензии и хронической тромбоэмболической легочной гипертензии. Consilium Medicum. 2019; 21 (10): 48–58. DOI: 10.26442/20751753.2019.10.190474
________________________________________________
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
Легочная гипертензия (ЛГ) – группа заболеваний, характеризующихся прогрессирующим повышением давления в легочных артериях и легочного сосудистого сопротивления, быстро приводящая к правожелудочковой сердечной недостаточности и гибели пациентов. Интерес к проблеме ЛГ обусловлен отсутствием точных эпидемиологических данных о распространенности ЛГ, быстро прогрессирующим течением с грозными осложнениями и внушительной смертностью. Если для одних групп (ЛГ вследствие патологии левых отделов сердца или заболеваний легких) все сводится к лечению и контролю основного заболевания, то для других (легочная артериальная гипертензия – ЛАГ или хроническая тромбоэмболическая легочная гипертензия – ХТЭЛГ) привлекательным подходом является специфическая терапия, учитывая злокачественный характер течения и сложность патогенеза ЛАГ. Риоцигуат – первый представитель нового класса ЛАГ-специфических препаратов, показанный для лечения некоторых форм ХТЭЛГ и ЛАГ, инновационное лекарственное средство, в исследованиях которого продемонстрирована высокая выживаемость пациентов. Целью статьи является предоставление современных данных по ведению и лечению пациентов, а также роли специфической терапии и месте риоцигуата в терапии пациентов с ЛАГ и ХТЭЛГ.
Ключевые слова: легочная гипертензия, легочная артериальная гипертензия, хроническая тромбоэмболическая легочная гипертензия, ЛАГ-специфическая терапия, риоцигуат.
Ключевые слова: легочная гипертензия, легочная артериальная гипертензия, хроническая тромбоэмболическая легочная гипертензия, ЛАГ-специфическая терапия, риоцигуат.
________________________________________________
Pulmonary hypertension (PH) is a group of diseases characterized by a progressive increase of pressure in the pulmonary arteries and pulmonary vascular resistance, quickly leading to the right ventricular heart failure and patient death. Increasing interest in the PH problem is due to the lack of epidemiological data on the prevalence of PH, rapidly progressing diseases with severe complications and considerable mortality. If for some groups of PH (PH associated with the left heart failure or lung diseases) it all boils down to treatment and control of the underlying disease, for others (pulmonary arterial hypertension – PAH or chronic thromboembolic pulmonary hypertension – CTEPH), an attractive approach is the specific therapy, given the malignant nature of the course and the complexity of the pathogenesis of PAH. Riociguat is the first representative of a new class of PAH-specific drugs, indicated for the treatment of CTEPH, and some forms of PAH, an innovative drug that has shown a high survival rate for patients. The purpose of this article is to provide contemporary data on the management and treatment of patients, as well as the role of specific therapy and the place of riociguat in the treatment of patients with PAH and CTEPH.
Key words: pulmonary hypertension, pulmonary arterial hypertension, chronic thromboembolic pulmonary hypertension, PAH-specific therapy, riociguat.
Key words: pulmonary hypertension, pulmonary arterial hypertension, chronic thromboembolic pulmonary hypertension, PAH-specific therapy, riociguat.
Полный текст
Список литературы
1. Simonneau G, Montani D, Celermajer DS et al. Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur Respir J 2019; 53: 1801913. https://doi.org/10.1183/13993003.01913-2018
2. Российское медицинское общество по артериальной гипертонии, РМОАГ. Клинические рекомендации «Легочная гипертензия», 2016 г. КР158 (доступно по ссылке: http://cr.rosminzdrav.ru/#!/recomend/136).
[Rossiiskoe meditsinskoe obshchestvo po arterial'noi gipertonii, RMOAG. Klinicheskie rekomendatsii "Legochnaia gipertenziia", 2016 g. KR158 (dostupno po ssylke: http://cr.rosminzdrav.ru/#!/recomend/136) (in Russian).]
3. Чазова И.Е., Мартынюк Т.В. Легочная гипертензия. М.: Практика, 2015; с. 17–108, 121–48, 189–227, 563–606.
[Chazova I.E., Martyniuk T.V. Pulmonary hypertension. Moscow, 2015; p. 17–108, 121–48, 189–227, 563–606 (in Russian).]
4. Чазова И.Е., Авдеев С.Н., Царева Н.А. и др. Клинические рекомендации по диагностике и лечению легочной гипертонии. Терапевтический архив. 2014; 86 (9): 4–23.
[Chazova I.E., Avdeev S.N., Tsareva N.A. et al. Klinicheskie rekomendatsii po diagnostike i lecheniiu legochnoi gipertonii.Therapeutic Archive. 2014; 86 (9): 4–23 (in Russian).]
5. Мартынюк Т.В. Легочная гипертензия: диагностика и лечение. М., 2018; с. 148.
[Martyniuk T.V. Pulmonary hypertension: diagnosis and treatment. Moscow, 2018; p. 148 (in Russian).]
6. Galie N, Humbert M, Vachiery JL et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS). Eur Respir J 2015; 46 (4): 903–75.
7. Авдеев С.Н. и др. Легочная гипертензия: руководство для врачей. М.: ГЭОТАР-Медиа, 2019; с. 386–406.
[Avdeev S.N. et al. Pulmonary hypertension: a guide for physicians. Moscow: GEOTAR-Media, 2019; p. 386–406 (in Russian).]
8. Taran I, Martynyuk T, Chazova I et al. Initial Riociguat Monotherapy and Transition from Sildenafil to Riociguat in Patients with Idiopathic Pulmonary Arterial Hypertension: Influence on Right Heart Remodeling and Right Ventricular–Pulmonary Arterial Coupling. Lung (2018) 196: 745–53. https://doi.org/10.1007/ s00408-018-0160-4.
9. D’Alonzo GE, Barst RJ, Ayres SM et al. Survival in patients with pulmonary hypertension: results from a national prospective registry. Ann Intern Med 1991; 115: 343–9.
10. Чазова И.Е., Архипова О.А., Мартынюк Т.В. Легочная артериальная гипертензия в России: анализ шестилетнего наблюдения по данным Национального регистра. Терапевтический архив. 2019; 91 (1): 25–31.
[Chazova I.E., Arkhipova O.A., Martyniuk T.V. Legochnaia arterial'naia gipertenziia v Rossii: analiz shestiletnego nabliudeniia po dannym Natsional'nogo registra. Therapeutic Archive. 2019; 91 (1): 25–31 (in Russian).]
11. Zhang M, Wang N, Zhai Z et al. Incidence and risk factors of chronic thromboembolic pulmonary hypertension after acute pulmonary embolism: a systematic review and meta-analysis of cohort studies. J Thorac Dis 2018; 10 (8): 4751–63. DOI: 10.21037/jtd.2018.07.106
12. Hoeper MM, Mayer E, Simonneau G, Rubin L J. Chronic thromboembolic pulmonary hypertension. Circulation 2006; 113: 2011–20.
13. Rubin LJ. Primary pulmonary hypertension. N Engl J Med 1997; 336: 111–7.
14. Yu Y, Yang L, Zhang Y et al. Incidence and risk factors of chronic thromboembolic pulmonary hypertension in patients with diagnosis of pulmonary embolism for the first time in real world. Clin Respir J 2018; 12: 2551–8. https://doi.org/10.1111/crj.12955
15. Беленков Ю.Н., Чазова И.Е. Первичная легочная гипертензия, М.: Нолидж, 1999.
[Belenkov Iu.N., Chazova I.E. Primary pulmonary hypertension. Moscow: Nolidzh, 1999 (in Russian).]
16. Чазова И.Е., Мартынюк Т.В. Легочная гипертензия. М.: Нолидж, 2016; с. 141.
[Chazova I.E., Martyniuk T.V. Pulmonary hypertension. Moscow, Nolidzh, 2016; p. 141 (in Russian).]
17. Наконечников С.Н., Зыков К.А., Мартынюк Т.В. и др. Профиль провоспалительных маркеров у пациентов с различными формами легочной гипертензии. Системные гипертензии, 2010; 7 (3): 61–7.
[Nakonechnikov S.N., Zykov K.A., Martyniuk T.V. et al. The proinflammatory markers pattern of patients with different forms of pulmonary. Systemic Hypertension. 2010; 7 (3): 61–7 (in Russian).]
18. Fedullo PF, Auger WR, Kerr KM et al. Chronic thromboembolic pulmonary hypertension. N Engl J Med 2001; 345: 1465–72.
19. Pengo V, Lensing AW, Prins MH et al. Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. N Engl J Med 2004; 350: 2257–64.
20. Rich S, Dantzker D, Ayres S et al. Primary pulmonary hypertension. A national prospective study. Ann Intern Med 1987; 107: 216–23.
21. Godfrey A, Cajigas H et al. A 55-Year-Old Woman With Pulmonary Hypertension, Worsening Dyspnea, and Chest Pain CHEST 2014; 145 (3): 642–5.
22. Мартынюк Т.В. Идиопатическая легочная гипертензия: клинико-патофизиологические особенности и возможности патогенетически обоснованной терапии. Автореф. дис. … д-ра мед. наук. М., 2013.
[Martyniuk T.V. Idiopaticheskaia legochnaia gipertenziia: kliniko-patofiziologicheskie osobennosti i vozmozhnosti patogeneticheski obosnovannoi terapii. Avtoref. dis. … d-ra med. nauk. Moscow, 2013 (in Russian).]
23. Чазова И.Е., Архипова О.А., Валиева З.С. и др. Легочная гипертензия в России: первые результаты национального регистра. Терапевтический архив. 2014; 86 (9): 56–64.
[Chazova I.E., Arkhipova O.A., Valieva Z.S. et al. Pulmonary hypertension in Russia: The first results of the national register. Therapeutic Archive. 2014; 86 (9): 56–64 (in Russian).]
24. Falletta C, Cascio C, Tuzzolino F et al. Accuracy of doppler echocardiography in measuring right-heart pressure in patients with pulmonary hypertension. Eur J Heart Fail 2010; 9: S33.
25. Мартынюк Т.В., Чазова И.Е. Первые Российские рекомендации по диагностике и лечению легочной гипертензии. Болезни сердца и сосудов. 2007; 4: 45–51.
[Martyniuk T.V., Chazova I.E. Pervye Rossiiskie rekomendatsii po diagnostike i lecheniiu legochnoi gipertenzii. Bolezni serdtsa i sosudov. 2007; 4: 45–51 (in Russian).]
26. Kim NH, Delcroix M, Jenkins DP et al. Chronic Thromboembolic Pulmonary Hypertension. J Am Coll Cardiol 2013; 62 (Suppl.): 92–9.
27. Мартынюк Т.В., Наконечников С.Н., Чазова И.Е. Актуальные вопросы современной комбинированной специфической терапии легочной артериальной гипертензии: за и против. Мед. совет. 2017; 5: 3–10.
[Martyniuk T.V., Nakonechnikov S.N., Chazova I.E. Aktual'nye voprosy sovremennoi kombinirovannoi spetsificheskoi terapii legochnoi arterial'noi gipertenzii: za i protiv. Med. sovet. 2017; 5: 3–10 (in Russian).]
28. Albania S, Biondia F, Stolfoa D et al. Chronic thromboembolic pulmonary hypertension (CTEPH): what do we know about it? A comprehensive review of the literature. J Cardiovasc Med 2019; 00 (00). DOI: 10.2459/JCM.0000000000000774
29. Konstantinides CV, Torbick A, Giancarlo Agnelli G et al. 2014 ESC Guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J 2014; 35: 3033–80.
30. Шмальц А.А., Горбачевский С.В. Биохимический путь оксида азота в терапии легочной артериальной гипертензии и результаты исследования RESPITE. Системные гипертензии. 2018; 15 (2): 72–6. DOI: 10.26442/2075-082X_2018.2.72-76
[Shmalts А.А., Gorbachevsky S.V. Nitrogen oxide biochemical pathway in pulmonary arterial hypertension therapy and REPLACE trial results. Systemic Hypertension. 2018; 15 (2): 72–6. DOI: 10.26442/2075-082X_2018.2.72-76 (in Russian).]
31. Wilkens H, Lang I, Behr J et al. Chronic thromboembolic pulmonary hypertension (CTEPH): Updated Recommendations of the Cologne Consensus Conference. Int J Cardiol 2011; 154 (Suppl. 1): S54–S60.
32. Torbicki A, Perrier A, Konstantinides S et al. Guidelines on the diagnosis and management of acute pulmonary embolism: The Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). Eur Heart J 2008; 28: 2276–315.
33. Российское медицинское общество по артериальной гипертонии. Клинические рекомендации. Хроническая тромбоэмболическая легочная гипертензия. М., 2016. http://cr.rosminzdrav.ru/#!/recomend/137
[Russian Medical Society for Arterial Hypertension. Clinical guidelines. Chronic thromboembolic pulmonary hypertension. Moscow, 2016. http://cr.rosminzdrav.ru/#!/recomend/137 (in Russian).]
34. Wieteska M et al. Outcome of medically versus surgically treated patients with chronic thromboembolic pulmonary hypertension. Clin Appl Thromb/Hemost 2016; 22 (1): 92–9.
35. Мартынюк Т.В., Дадачева З.Х., Чазова И.Е. Возможности медикаментозного лечения хронической тромбоэмболической легочной гипертензии. Специализированный мед. журнал. Атеротромбоз. 2015; 1: 87–98.
[Martyniuk T.V., Dadacheva Z.Kh., Chazova I.E. Vozmozhnosti medikamentoznogo lecheniia khronicheskoi tromboembolicheskoi legochnoi gipertenzii. Spetsializirovannyi med. zhurnal. Aterotromboz. 2015; 1: 87–98 (in Russian).]
36. McLaughlin W, Archer SL, Badesch DB et al.; ACCF/AHA.ACCF/AHA 2009 Expert Consensus Document on Pulmonary Hypertension. A Report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association. Developed in Collaboration With the American College of Chest Physicians, American Thoracic Society, Inc., and the Pulmonary Hypertension Association. Circulation 2009; 119 (16): 2250–94.
37. Ghofrani H-A et al. Riociguat for the Treatment of Pulmonary Arterial Hypertension. N Engl J Med 2013; 369: 330–40.
38. Rubin LJ et al. Riociguat for the treatment of pulmonary arterial hypertension: a long-term extension study (PATENT-2). Eur Respir J 2015; 45: 1211–3.
39. Ghofrani H-A et al. Predictors of long-term outcomes in patients treated with riociguat for pulmonary arterial hypertension: data from the PATENT-2 open-label, randomised, long-term extension trial. Lancet Respir Med 2016; 4: 361–71. http://dx.doi.org/10.1016/S2213-2600(16)30019-4
40. Halank M et al. Riociguat for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: Results from a phase II long-term extension study. Respir Med 2017; 128: 50–6.
41. Liu H et al. Efficacy and Safety of Pulmonary Arterial Hypertension-specific Therapy in Pulmonary Arterial Hypertension. A Meta-analysis of Randomized Controlled Trials. Chest 2016; 150 (2): 353–66.
42. Платонов Д.Ю., Царева Н.А., Авдеев С.Н. Выживаемость пациентов с легочной артериальной гипертензией на фоне терапии таблетированными ЛАГ-специфическими препаратами. Системные гипертензии. 2017; 14 (3): 58–64.
[Platonov D.Yu., Tsareva N.A., Avdeev S.N. Survival of patients with pulmonary arterial hypertension during therapy PAH-specific drugs. Systemic Hypertension. 2017; 14 (3): 58–64. DOI: 10.26442/2075-082X_14.3.58-64 (in Russian).]
43. Hoeper MM et al. Targeted therapy of pulmonary arterial hypertension: Updated recommendations from the Cologne Consensus Conference 2018. Int J Cardiol 2018. https://doi.org/10.1016/j.ijcard.2018.08.082
44. Guha M. First-in-class guanylate cyclase stimulator approved for PAH. Nat Biotechnol 2013; 31: 1064.
45. Инструкция по медицинскому применению лекарственного препарата Адемпас. ЛП-002639 от 05.10.2017 г. (доступно по ссылке: https://grls.rosminzdrav.ru/GRLS.aspx?RegNumber=
&MnnR=%d0%a0%d0%b8%d0%be%d1%86%d0%b8%d0%b3%d1%83%d0%b0%d1%82&lf=&TradeNmR=&OwnerName=&MnfOrg=&MnfOrgCountry=&isfs=0&isND=-1®type=1%2c&pageSize=10&order=RegDate&orderType=desc&pageNum=1
[Instruktsiia po meditsinskomu primeneniiu lekarstvennogo preparata Adempas. LP-002639 ot 05.10.2017 g. (dostupno po ssylke: https://grls.rosminzdrav.ru/GRLS.aspx?RegNumber=
&MnnR=%d0%a0%d0%b8%d0%be%d1%86%d0%b8%d0%b3%d1%83%d0%b0%d1%82&lf=&TradeNmR=&OwnerName=&MnfOrg=&MnfOrgCountry=&isfs=0&isND=-1®type=1%2c&pageSize=10&order=RegDate&orderType=desc&pageNum=1 (in Russian).]
46. Olschewski H, Simonneau G, Galiè N et al. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 2002; 347 (5): 322–9.
47. Шмальц А.А., Горбачевский С.В. Риоцигуат и силденафил в лечении легочной гипертензии: сходства и различия. Пульмонология. 2016; 26 (1): 85–91.
[Shmal'ts A.A., Gorbachevskii S.V. Riotsiguat i sildenafil v lechenii legochnoi gipertenzii: skhodstva i razlichiia. Pul'monologiia. 2016; 26 (1): 85–91 (in Russian).]
48. Мершин К.В., Мартынюк Т.В. Место медикаментозной терапии в лечении хронической тромбоэмболической легочной гипертензии. Евразийский кардиол. журнал. 2014; 1: 113–8.
[Mershin K.V., Martyniuk T.V. Mesto medikamentoznoi terapii v lechenii khronicheskoi tromboembolicheskoi legochnoi gipertenzii. Evraziiskii kardiol. zhurnal. 2014; 1: 113–8 (in Russian).]
49. Hoeper MM. Pharmacological therapy for patients with chronic thromboembolic pulmonary hypertension. Eur Respir Rev 2015; 24: 272–82.
50. Ghofrani HA, Hoeper MM, Halank M et al. Riociguat for chronic Thromboembolic pulmonary hypertension and pulmonary arterial hypertension: A phase II study. Eur Respir J 2010; 36: 792–9.
51. Ghofrani HA, D’Armini AM, Grimminger F et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. N Engl J Med 2013; 369: 319–29.
52. McLaughlin W, Jansa P, Jens E et al. Riociguat in patients with chronic thromboembolic pulmonary hypertension: results from an early access study. BMC Pulmonary Med 2017; 17: 216.
53. Simonneau G, D’Armini AM, Ghofrani H-A et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension: a long-term extension study (CHEST-2). Eur Respir J 2014; in press. DOI: 10.1183/09031936.00087114
54. Marra AM, Halank M, Benjamin N et al. Right ventricular size and function under riociguat in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension (the RIVER study). Respir Res 2018; 19: 258. https://doi.org/10.1186/s12931-018-0957-y
55. Hatano M et al. Significant Improvement Of Oxygen Saturation Of Peripheral Artery During Exercise In Patients With CTeph Treated With Riociguat. Am J Respir Crit Care Med 2016; 193: A5654. https://www.atsjournals.org/doi/abs/10.1164/ajrccm-conference.2016.193.1_MeetingAbstracts.A5654
56. Kambakamba A et al. Acute hemodynamic effects of riociguat in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. Eur Respir J 2018; 52 (Suppl. 62): PA3049. DOI: 10.1183/13993003.congress-2018.PA3049
57. Thenappan T et al. Survival in pulmonary arterial hypertension: a reappraisal of the NIH risk stratification equation. Eur Respir J 2010; 35: 1079–87.
58. European medicines agency. Committee for Medicinal Products for Human Use (CHMP) assessment report. EMA/CHMP/734750/2013. 23 January 2014. Adempas. Procedure No. EMEA/H/C/002737/0000.
59. Reichenberger F, Voswinckel R, Enke B et al. Long-term treatment with sildenafil in chronic thromboembolic pulmonary hypertension. Eur Respir J 2007; 30: 922–7.
2. Rossiiskoe meditsinskoe obshchestvo po arterial'noi gipertonii, RMOAG. Klinicheskie rekomendatsii "Legochnaia gipertenziia", 2016 g. KR158 (dostupno po ssylke: http://cr.rosminzdrav.ru/#!/recomend/136) (in Russian).
3. Chazova I.E., Martyniuk T.V. Pulmonary hypertension. Moscow, 2015; p. 17–108, 121–48, 189–227, 563–606 (in Russian).
4. Chazova I.E., Avdeev S.N., Tsareva N.A. et al. Klinicheskie rekomendatsii po diagnostike i lecheniiu legochnoi gipertonii.Therapeutic Archive. 2014; 86 (9): 4–23 (in Russian).
5. Martyniuk T.V. Pulmonary hypertension: diagnosis and treatment. Moscow, 2018; p. 148 (in Russian).
6. Galie N, Humbert M, Vachiery JL et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS). Eur Respir J 2015; 46 (4): 903–75.
7. Avdeev S.N. et al. Pulmonary hypertension: a guide for physicians. Moscow: GEOTAR-Media, 2019; p. 386–406 (in Russian).
8. Taran I, Martynyuk T, Chazova I et al. Initial Riociguat Monotherapy and Transition from Sildenafil to Riociguat in Patients with Idiopathic Pulmonary Arterial Hypertension: Influence on Right Heart Remodeling and Right Ventricular–Pulmonary Arterial Coupling. Lung (2018) 196: 745–53. https://doi.org/10.1007/ s00408-018-0160-4.
9. D’Alonzo GE, Barst RJ, Ayres SM et al. Survival in patients with pulmonary hypertension: results from a national prospective registry. Ann Intern Med 1991; 115: 343–9.
10. Chazova I.E., Arkhipova O.A., Martyniuk T.V. Legochnaia arterial'naia gipertenziia v Rossii: analiz shestiletnego nabliudeniia po dannym Natsional'nogo registra. Therapeutic Archive. 2019; 91 (1): 25–31 (in Russian).
11. Zhang M, Wang N, Zhai Z et al. Incidence and risk factors of chronic thromboembolic pulmonary hypertension after acute pulmonary embolism: a systematic review and meta-analysis of cohort studies. J Thorac Dis 2018; 10 (8): 4751–63. DOI: 10.21037/jtd.2018.07.106
12. Hoeper MM, Mayer E, Simonneau G, Rubin L J. Chronic thromboembolic pulmonary hypertension. Circulation 2006; 113: 2011–20.
13. Rubin LJ. Primary pulmonary hypertension. N Engl J Med 1997; 336: 111–7.
14. Yu Y, Yang L, Zhang Y et al. Incidence and risk factors of chronic thromboembolic pulmonary hypertension in patients with diagnosis of pulmonary embolism for the first time in real world. Clin Respir J 2018; 12: 2551–8. https://doi.org/10.1111/crj.12955
15. Belenkov Iu.N., Chazova I.E. Primary pulmonary hypertension. Moscow: Nolidzh, 1999 (in Russian).
16. Chazova I.E., Martyniuk T.V. Pulmonary hypertension. Moscow, Nolidzh, 2016; p. 141 (in Russian).
17. Nakonechnikov S.N., Zykov K.A., Martyniuk T.V. et al. The proinflammatory markers pattern of patients with different forms of pulmonary. Systemic Hypertension. 2010; 7 (3): 61–7 (in Russian).
18. Fedullo PF, Auger WR, Kerr KM et al. Chronic thromboembolic pulmonary hypertension. N Engl J Med 2001; 345: 1465–72.
19. Pengo V, Lensing AW, Prins MH et al. Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. N Engl J Med 2004; 350: 2257–64.
20. Rich S, Dantzker D, Ayres S et al. Primary pulmonary hypertension. A national prospective study. Ann Intern Med 1987; 107: 216–23.
21. Godfrey A, Cajigas H et al. A 55-Year-Old Woman With Pulmonary Hypertension, Worsening Dyspnea, and Chest Pain CHEST 2014; 145 (3): 642–5.
22. Martyniuk T.V. Idiopaticheskaia legochnaia gipertenziia: kliniko-patofiziologicheskie osobennosti i vozmozhnosti patogeneticheski obosnovannoi terapii. Avtoref. dis. … d-ra med. nauk. Moscow, 2013 (in Russian).
23. Chazova I.E., Arkhipova O.A., Valieva Z.S. et al. Pulmonary hypertension in Russia: The first results of the national register. Therapeutic Archive. 2014; 86 (9): 56–64 (in Russian).
24. Falletta C, Cascio C, Tuzzolino F et al. Accuracy of doppler echocardiography in measuring right-heart pressure in patients with pulmonary hypertension. Eur J Heart Fail 2010; 9: S33.
25. Martyniuk T.V., Chazova I.E. Pervye Rossiiskie rekomendatsii po diagnostike i lecheniiu legochnoi gipertenzii. Bolezni serdtsa i sosudov. 2007; 4: 45–51 (in Russian).
26. Kim NH, Delcroix M, Jenkins DP et al. Chronic Thromboembolic Pulmonary Hypertension. J Am Coll Cardiol 2013; 62 (Suppl.): 92–9.
27. Martyniuk T.V., Nakonechnikov S.N., Chazova I.E. Aktual'nye voprosy sovremennoi kombinirovannoi spetsificheskoi terapii legochnoi arterial'noi gipertenzii: za i protiv. Med. sovet. 2017; 5: 3–10 (in Russian).
28. Albania S, Biondia F, Stolfoa D et al. Chronic thromboembolic pulmonary hypertension (CTEPH): what do we know about it? A comprehensive review of the literature. J Cardiovasc Med 2019; 00 (00). DOI: 10.2459/JCM.0000000000000774
29. Konstantinides CV, Torbick A, Giancarlo Agnelli G et al. 2014 ESC Guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J 2014; 35: 3033–80.
30. Shmalts А.А., Gorbachevsky S.V. Nitrogen oxide biochemical pathway in pulmonary arterial hypertension therapy and REPLACE trial results. Systemic Hypertension. 2018; 15 (2): 72–6. DOI: 10.26442/2075-082X_2018.2.72-76 (in Russian).
31. Wilkens H, Lang I, Behr J et al. Chronic thromboembolic pulmonary hypertension (CTEPH): Updated Recommendations of the Cologne Consensus Conference. Int J Cardiol 2011; 154 (Suppl. 1): S54–S60.
32. Torbicki A, Perrier A, Konstantinides S et al. Guidelines on the diagnosis and management of acute pulmonary embolism: The Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). Eur Heart J 2008; 28: 2276–315.
33. Russian Medical Society for Arterial Hypertension. Clinical guidelines. Chronic thromboembolic pulmonary hypertension. Moscow, 2016. http://cr.rosminzdrav.ru/#!/recomend/137 (in Russian).
34. Wieteska M et al. Outcome of medically versus surgically treated patients with chronic thromboembolic pulmonary hypertension. Clin Appl Thromb/Hemost 2016; 22 (1): 92–9.
35. Martyniuk T.V., Dadacheva Z.Kh., Chazova I.E. Vozmozhnosti medikamentoznogo lecheniia khronicheskoi tromboembolicheskoi legochnoi gipertenzii. Spetsializirovannyi med. zhurnal. Aterotromboz. 2015; 1: 87–98 (in Russian).
36. McLaughlin W, Archer SL, Badesch DB et al.; ACCF/AHA.ACCF/AHA 2009 Expert Consensus Document on Pulmonary Hypertension. A Report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association. Developed in Collaboration With the American College of Chest Physicians, American Thoracic Society, Inc., and the Pulmonary Hypertension Association. Circulation 2009; 119 (16): 2250–94.
37. Ghofrani H-A et al. Riociguat for the Treatment of Pulmonary Arterial Hypertension. N Engl J Med 2013; 369: 330–40.
38. Rubin LJ et al. Riociguat for the treatment of pulmonary arterial hypertension: a long-term extension study (PATENT-2). Eur Respir J 2015; 45: 1211–3.
39. Ghofrani H-A et al. Predictors of long-term outcomes in patients treated with riociguat for pulmonary arterial hypertension: data from the PATENT-2 open-label, randomised, long-term extension trial. Lancet Respir Med 2016; 4: 361–71. http://dx.doi.org/10.1016/S2213-2600(16)30019-4
40. Halank M et al. Riociguat for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: Results from a phase II long-term extension study. Respir Med 2017; 128: 50–6.
41. Liu H et al. Efficacy and Safety of Pulmonary Arterial Hypertension-specific Therapy in Pulmonary Arterial Hypertension. A Meta-analysis of Randomized Controlled Trials. Chest 2016; 150 (2): 353–66.
42. Platonov D.Yu., Tsareva N.A., Avdeev S.N. Survival of patients with pulmonary arterial hypertension during therapy PAH-specific drugs. Systemic Hypertension. 2017; 14 (3): 58–64. DOI: 10.26442/2075-082X_14.3.58-64 (in Russian).
43. Hoeper MM et al. Targeted therapy of pulmonary arterial hypertension: Updated recommendations from the Cologne Consensus Conference 2018. Int J Cardiol 2018. https://doi.org/10.1016/j.ijcard.2018.08.082
44. Guha M. First-in-class guanylate cyclase stimulator approved for PAH. Nat Biotechnol 2013; 31: 1064.
45. Instruktsiia po meditsinskomu primeneniiu lekarstvennogo preparata Adempas. LP-002639 ot 05.10.2017 g. (dostupno po ssylke: https://grls.rosminzdrav.ru/GRLS.aspx?RegNumber=
&MnnR=%d0%a0%d0%b8%d0%be%d1%86%d0%b8%d0%b3%d1%83%d0%b0%d1%82&lf=&TradeNmR=&OwnerName=&MnfOrg=&MnfOrgCountry=&isfs=0&isND=-1®type=1%2c&pageSize=10&order=RegDate&orderType=desc&pageNum=1 (in Russian).
46. Olschewski H, Simonneau G, Galiè N et al. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 2002; 347 (5): 322–9.
47. Shmal'ts A.A., Gorbachevskii S.V. Riotsiguat i sildenafil v lechenii legochnoi gipertenzii: skhodstva i razlichiia. Pul'monologiia. 2016; 26 (1): 85–91 (in Russian).
48. Mershin K.V., Martyniuk T.V. Mesto medikamentoznoi terapii v lechenii khronicheskoi tromboembolicheskoi legochnoi gipertenzii. Evraziiskii kardiol. zhurnal. 2014; 1: 113–8 (in Russian).
49. Hoeper MM. Pharmacological therapy for patients with chronic thromboembolic pulmonary hypertension. Eur Respir Rev 2015; 24: 272–82.
50. Ghofrani HA, Hoeper MM, Halank M et al. Riociguat for chronic Thromboembolic pulmonary hypertension and pulmonary arterial hypertension: A phase II study. Eur Respir J 2010; 36: 792–9.
51. Ghofrani HA, D’Armini AM, Grimminger F et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. N Engl J Med 2013; 369: 319–29.
52. McLaughlin W, Jansa P, Jens E et al. Riociguat in patients with chronic thromboembolic pulmonary hypertension: results from an early access study. BMC Pulmonary Med 2017; 17: 216.
53. Simonneau G, D’Armini AM, Ghofrani H-A et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension: a long-term extension study (CHEST-2). Eur Respir J 2014; in press. DOI: 10.1183/09031936.00087114
54. Marra AM, Halank M, Benjamin N et al. Right ventricular size and function under riociguat in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension (the RIVER study). Respir Res 2018; 19: 258. https://doi.org/10.1186/s12931-018-0957-y
55. Hatano M et al. Significant Improvement Of Oxygen Saturation Of Peripheral Artery During Exercise In Patients With CTeph Treated With Riociguat. Am J Respir Crit Care Med 2016; 193: A5654. https://www.atsjournals.org/doi/abs/10.1164/ajrccm-conference.2016.193.1_MeetingAbstracts.A5654
56. Kambakamba A et al. Acute hemodynamic effects of riociguat in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. Eur Respir J 2018; 52 (Suppl. 62): PA3049. DOI: 10.1183/13993003.congress-2018.PA3049
57. Thenappan T et al. Survival in pulmonary arterial hypertension: a reappraisal of the NIH risk stratification equation. Eur Respir J 2010; 35: 1079–87.
58. European medicines agency. Committee for Medicinal Products for Human Use (CHMP) assessment report. EMA/CHMP/734750/2013. 23 January 2014. Adempas. Procedure No. EMEA/H/C/002737/0000.
59. Reichenberger F, Voswinckel R, Enke B et al. Long-term treatment with sildenafil in chronic thromboembolic pulmonary hypertension. Eur Respir J 2007; 30: 922–7.
2. Российское медицинское общество по артериальной гипертонии, РМОАГ. Клинические рекомендации «Легочная гипертензия», 2016 г. КР158 (доступно по ссылке: http://cr.rosminzdrav.ru/#!/recomend/136).
[Rossiiskoe meditsinskoe obshchestvo po arterial'noi gipertonii, RMOAG. Klinicheskie rekomendatsii "Legochnaia gipertenziia", 2016 g. KR158 (dostupno po ssylke: http://cr.rosminzdrav.ru/#!/recomend/136) (in Russian).]
3. Чазова И.Е., Мартынюк Т.В. Легочная гипертензия. М.: Практика, 2015; с. 17–108, 121–48, 189–227, 563–606.
[Chazova I.E., Martyniuk T.V. Pulmonary hypertension. Moscow, 2015; p. 17–108, 121–48, 189–227, 563–606 (in Russian).]
4. Чазова И.Е., Авдеев С.Н., Царева Н.А. и др. Клинические рекомендации по диагностике и лечению легочной гипертонии. Терапевтический архив. 2014; 86 (9): 4–23.
[Chazova I.E., Avdeev S.N., Tsareva N.A. et al. Klinicheskie rekomendatsii po diagnostike i lecheniiu legochnoi gipertonii.Therapeutic Archive. 2014; 86 (9): 4–23 (in Russian).]
5. Мартынюк Т.В. Легочная гипертензия: диагностика и лечение. М., 2018; с. 148.
[Martyniuk T.V. Pulmonary hypertension: diagnosis and treatment. Moscow, 2018; p. 148 (in Russian).]
6. Galie N, Humbert M, Vachiery JL et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS). Eur Respir J 2015; 46 (4): 903–75.
7. Авдеев С.Н. и др. Легочная гипертензия: руководство для врачей. М.: ГЭОТАР-Медиа, 2019; с. 386–406.
[Avdeev S.N. et al. Pulmonary hypertension: a guide for physicians. Moscow: GEOTAR-Media, 2019; p. 386–406 (in Russian).]
8. Taran I, Martynyuk T, Chazova I et al. Initial Riociguat Monotherapy and Transition from Sildenafil to Riociguat in Patients with Idiopathic Pulmonary Arterial Hypertension: Influence on Right Heart Remodeling and Right Ventricular–Pulmonary Arterial Coupling. Lung (2018) 196: 745–53. https://doi.org/10.1007/ s00408-018-0160-4.
9. D’Alonzo GE, Barst RJ, Ayres SM et al. Survival in patients with pulmonary hypertension: results from a national prospective registry. Ann Intern Med 1991; 115: 343–9.
10. Чазова И.Е., Архипова О.А., Мартынюк Т.В. Легочная артериальная гипертензия в России: анализ шестилетнего наблюдения по данным Национального регистра. Терапевтический архив. 2019; 91 (1): 25–31.
[Chazova I.E., Arkhipova O.A., Martyniuk T.V. Legochnaia arterial'naia gipertenziia v Rossii: analiz shestiletnego nabliudeniia po dannym Natsional'nogo registra. Therapeutic Archive. 2019; 91 (1): 25–31 (in Russian).]
11. Zhang M, Wang N, Zhai Z et al. Incidence and risk factors of chronic thromboembolic pulmonary hypertension after acute pulmonary embolism: a systematic review and meta-analysis of cohort studies. J Thorac Dis 2018; 10 (8): 4751–63. DOI: 10.21037/jtd.2018.07.106
12. Hoeper MM, Mayer E, Simonneau G, Rubin L J. Chronic thromboembolic pulmonary hypertension. Circulation 2006; 113: 2011–20.
13. Rubin LJ. Primary pulmonary hypertension. N Engl J Med 1997; 336: 111–7.
14. Yu Y, Yang L, Zhang Y et al. Incidence and risk factors of chronic thromboembolic pulmonary hypertension in patients with diagnosis of pulmonary embolism for the first time in real world. Clin Respir J 2018; 12: 2551–8. https://doi.org/10.1111/crj.12955
15. Беленков Ю.Н., Чазова И.Е. Первичная легочная гипертензия, М.: Нолидж, 1999.
[Belenkov Iu.N., Chazova I.E. Primary pulmonary hypertension. Moscow: Nolidzh, 1999 (in Russian).]
16. Чазова И.Е., Мартынюк Т.В. Легочная гипертензия. М.: Нолидж, 2016; с. 141.
[Chazova I.E., Martyniuk T.V. Pulmonary hypertension. Moscow, Nolidzh, 2016; p. 141 (in Russian).]
17. Наконечников С.Н., Зыков К.А., Мартынюк Т.В. и др. Профиль провоспалительных маркеров у пациентов с различными формами легочной гипертензии. Системные гипертензии, 2010; 7 (3): 61–7.
[Nakonechnikov S.N., Zykov K.A., Martyniuk T.V. et al. The proinflammatory markers pattern of patients with different forms of pulmonary. Systemic Hypertension. 2010; 7 (3): 61–7 (in Russian).]
18. Fedullo PF, Auger WR, Kerr KM et al. Chronic thromboembolic pulmonary hypertension. N Engl J Med 2001; 345: 1465–72.
19. Pengo V, Lensing AW, Prins MH et al. Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. N Engl J Med 2004; 350: 2257–64.
20. Rich S, Dantzker D, Ayres S et al. Primary pulmonary hypertension. A national prospective study. Ann Intern Med 1987; 107: 216–23.
21. Godfrey A, Cajigas H et al. A 55-Year-Old Woman With Pulmonary Hypertension, Worsening Dyspnea, and Chest Pain CHEST 2014; 145 (3): 642–5.
22. Мартынюк Т.В. Идиопатическая легочная гипертензия: клинико-патофизиологические особенности и возможности патогенетически обоснованной терапии. Автореф. дис. … д-ра мед. наук. М., 2013.
[Martyniuk T.V. Idiopaticheskaia legochnaia gipertenziia: kliniko-patofiziologicheskie osobennosti i vozmozhnosti patogeneticheski obosnovannoi terapii. Avtoref. dis. … d-ra med. nauk. Moscow, 2013 (in Russian).]
23. Чазова И.Е., Архипова О.А., Валиева З.С. и др. Легочная гипертензия в России: первые результаты национального регистра. Терапевтический архив. 2014; 86 (9): 56–64.
[Chazova I.E., Arkhipova O.A., Valieva Z.S. et al. Pulmonary hypertension in Russia: The first results of the national register. Therapeutic Archive. 2014; 86 (9): 56–64 (in Russian).]
24. Falletta C, Cascio C, Tuzzolino F et al. Accuracy of doppler echocardiography in measuring right-heart pressure in patients with pulmonary hypertension. Eur J Heart Fail 2010; 9: S33.
25. Мартынюк Т.В., Чазова И.Е. Первые Российские рекомендации по диагностике и лечению легочной гипертензии. Болезни сердца и сосудов. 2007; 4: 45–51.
[Martyniuk T.V., Chazova I.E. Pervye Rossiiskie rekomendatsii po diagnostike i lecheniiu legochnoi gipertenzii. Bolezni serdtsa i sosudov. 2007; 4: 45–51 (in Russian).]
26. Kim NH, Delcroix M, Jenkins DP et al. Chronic Thromboembolic Pulmonary Hypertension. J Am Coll Cardiol 2013; 62 (Suppl.): 92–9.
27. Мартынюк Т.В., Наконечников С.Н., Чазова И.Е. Актуальные вопросы современной комбинированной специфической терапии легочной артериальной гипертензии: за и против. Мед. совет. 2017; 5: 3–10.
[Martyniuk T.V., Nakonechnikov S.N., Chazova I.E. Aktual'nye voprosy sovremennoi kombinirovannoi spetsificheskoi terapii legochnoi arterial'noi gipertenzii: za i protiv. Med. sovet. 2017; 5: 3–10 (in Russian).]
28. Albania S, Biondia F, Stolfoa D et al. Chronic thromboembolic pulmonary hypertension (CTEPH): what do we know about it? A comprehensive review of the literature. J Cardiovasc Med 2019; 00 (00). DOI: 10.2459/JCM.0000000000000774
29. Konstantinides CV, Torbick A, Giancarlo Agnelli G et al. 2014 ESC Guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J 2014; 35: 3033–80.
30. Шмальц А.А., Горбачевский С.В. Биохимический путь оксида азота в терапии легочной артериальной гипертензии и результаты исследования RESPITE. Системные гипертензии. 2018; 15 (2): 72–6. DOI: 10.26442/2075-082X_2018.2.72-76
[Shmalts А.А., Gorbachevsky S.V. Nitrogen oxide biochemical pathway in pulmonary arterial hypertension therapy and REPLACE trial results. Systemic Hypertension. 2018; 15 (2): 72–6. DOI: 10.26442/2075-082X_2018.2.72-76 (in Russian).]
31. Wilkens H, Lang I, Behr J et al. Chronic thromboembolic pulmonary hypertension (CTEPH): Updated Recommendations of the Cologne Consensus Conference. Int J Cardiol 2011; 154 (Suppl. 1): S54–S60.
32. Torbicki A, Perrier A, Konstantinides S et al. Guidelines on the diagnosis and management of acute pulmonary embolism: The Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). Eur Heart J 2008; 28: 2276–315.
33. Российское медицинское общество по артериальной гипертонии. Клинические рекомендации. Хроническая тромбоэмболическая легочная гипертензия. М., 2016. http://cr.rosminzdrav.ru/#!/recomend/137
[Russian Medical Society for Arterial Hypertension. Clinical guidelines. Chronic thromboembolic pulmonary hypertension. Moscow, 2016. http://cr.rosminzdrav.ru/#!/recomend/137 (in Russian).]
34. Wieteska M et al. Outcome of medically versus surgically treated patients with chronic thromboembolic pulmonary hypertension. Clin Appl Thromb/Hemost 2016; 22 (1): 92–9.
35. Мартынюк Т.В., Дадачева З.Х., Чазова И.Е. Возможности медикаментозного лечения хронической тромбоэмболической легочной гипертензии. Специализированный мед. журнал. Атеротромбоз. 2015; 1: 87–98.
[Martyniuk T.V., Dadacheva Z.Kh., Chazova I.E. Vozmozhnosti medikamentoznogo lecheniia khronicheskoi tromboembolicheskoi legochnoi gipertenzii. Spetsializirovannyi med. zhurnal. Aterotromboz. 2015; 1: 87–98 (in Russian).]
36. McLaughlin W, Archer SL, Badesch DB et al.; ACCF/AHA.ACCF/AHA 2009 Expert Consensus Document on Pulmonary Hypertension. A Report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association. Developed in Collaboration With the American College of Chest Physicians, American Thoracic Society, Inc., and the Pulmonary Hypertension Association. Circulation 2009; 119 (16): 2250–94.
37. Ghofrani H-A et al. Riociguat for the Treatment of Pulmonary Arterial Hypertension. N Engl J Med 2013; 369: 330–40.
38. Rubin LJ et al. Riociguat for the treatment of pulmonary arterial hypertension: a long-term extension study (PATENT-2). Eur Respir J 2015; 45: 1211–3.
39. Ghofrani H-A et al. Predictors of long-term outcomes in patients treated with riociguat for pulmonary arterial hypertension: data from the PATENT-2 open-label, randomised, long-term extension trial. Lancet Respir Med 2016; 4: 361–71. http://dx.doi.org/10.1016/S2213-2600(16)30019-4
40. Halank M et al. Riociguat for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: Results from a phase II long-term extension study. Respir Med 2017; 128: 50–6.
41. Liu H et al. Efficacy and Safety of Pulmonary Arterial Hypertension-specific Therapy in Pulmonary Arterial Hypertension. A Meta-analysis of Randomized Controlled Trials. Chest 2016; 150 (2): 353–66.
42. Платонов Д.Ю., Царева Н.А., Авдеев С.Н. Выживаемость пациентов с легочной артериальной гипертензией на фоне терапии таблетированными ЛАГ-специфическими препаратами. Системные гипертензии. 2017; 14 (3): 58–64.
[Platonov D.Yu., Tsareva N.A., Avdeev S.N. Survival of patients with pulmonary arterial hypertension during therapy PAH-specific drugs. Systemic Hypertension. 2017; 14 (3): 58–64. DOI: 10.26442/2075-082X_14.3.58-64 (in Russian).]
43. Hoeper MM et al. Targeted therapy of pulmonary arterial hypertension: Updated recommendations from the Cologne Consensus Conference 2018. Int J Cardiol 2018. https://doi.org/10.1016/j.ijcard.2018.08.082
44. Guha M. First-in-class guanylate cyclase stimulator approved for PAH. Nat Biotechnol 2013; 31: 1064.
45. Инструкция по медицинскому применению лекарственного препарата Адемпас. ЛП-002639 от 05.10.2017 г. (доступно по ссылке: https://grls.rosminzdrav.ru/GRLS.aspx?RegNumber=
&MnnR=%d0%a0%d0%b8%d0%be%d1%86%d0%b8%d0%b3%d1%83%d0%b0%d1%82&lf=&TradeNmR=&OwnerName=&MnfOrg=&MnfOrgCountry=&isfs=0&isND=-1®type=1%2c&pageSize=10&order=RegDate&orderType=desc&pageNum=1
[Instruktsiia po meditsinskomu primeneniiu lekarstvennogo preparata Adempas. LP-002639 ot 05.10.2017 g. (dostupno po ssylke: https://grls.rosminzdrav.ru/GRLS.aspx?RegNumber=
&MnnR=%d0%a0%d0%b8%d0%be%d1%86%d0%b8%d0%b3%d1%83%d0%b0%d1%82&lf=&TradeNmR=&OwnerName=&MnfOrg=&MnfOrgCountry=&isfs=0&isND=-1®type=1%2c&pageSize=10&order=RegDate&orderType=desc&pageNum=1 (in Russian).]
46. Olschewski H, Simonneau G, Galiè N et al. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 2002; 347 (5): 322–9.
47. Шмальц А.А., Горбачевский С.В. Риоцигуат и силденафил в лечении легочной гипертензии: сходства и различия. Пульмонология. 2016; 26 (1): 85–91.
[Shmal'ts A.A., Gorbachevskii S.V. Riotsiguat i sildenafil v lechenii legochnoi gipertenzii: skhodstva i razlichiia. Pul'monologiia. 2016; 26 (1): 85–91 (in Russian).]
48. Мершин К.В., Мартынюк Т.В. Место медикаментозной терапии в лечении хронической тромбоэмболической легочной гипертензии. Евразийский кардиол. журнал. 2014; 1: 113–8.
[Mershin K.V., Martyniuk T.V. Mesto medikamentoznoi terapii v lechenii khronicheskoi tromboembolicheskoi legochnoi gipertenzii. Evraziiskii kardiol. zhurnal. 2014; 1: 113–8 (in Russian).]
49. Hoeper MM. Pharmacological therapy for patients with chronic thromboembolic pulmonary hypertension. Eur Respir Rev 2015; 24: 272–82.
50. Ghofrani HA, Hoeper MM, Halank M et al. Riociguat for chronic Thromboembolic pulmonary hypertension and pulmonary arterial hypertension: A phase II study. Eur Respir J 2010; 36: 792–9.
51. Ghofrani HA, D’Armini AM, Grimminger F et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. N Engl J Med 2013; 369: 319–29.
52. McLaughlin W, Jansa P, Jens E et al. Riociguat in patients with chronic thromboembolic pulmonary hypertension: results from an early access study. BMC Pulmonary Med 2017; 17: 216.
53. Simonneau G, D’Armini AM, Ghofrani H-A et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension: a long-term extension study (CHEST-2). Eur Respir J 2014; in press. DOI: 10.1183/09031936.00087114
54. Marra AM, Halank M, Benjamin N et al. Right ventricular size and function under riociguat in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension (the RIVER study). Respir Res 2018; 19: 258. https://doi.org/10.1186/s12931-018-0957-y
55. Hatano M et al. Significant Improvement Of Oxygen Saturation Of Peripheral Artery During Exercise In Patients With CTeph Treated With Riociguat. Am J Respir Crit Care Med 2016; 193: A5654. https://www.atsjournals.org/doi/abs/10.1164/ajrccm-conference.2016.193.1_MeetingAbstracts.A5654
56. Kambakamba A et al. Acute hemodynamic effects of riociguat in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. Eur Respir J 2018; 52 (Suppl. 62): PA3049. DOI: 10.1183/13993003.congress-2018.PA3049
57. Thenappan T et al. Survival in pulmonary arterial hypertension: a reappraisal of the NIH risk stratification equation. Eur Respir J 2010; 35: 1079–87.
58. European medicines agency. Committee for Medicinal Products for Human Use (CHMP) assessment report. EMA/CHMP/734750/2013. 23 January 2014. Adempas. Procedure No. EMEA/H/C/002737/0000.
59. Reichenberger F, Voswinckel R, Enke B et al. Long-term treatment with sildenafil in chronic thromboembolic pulmonary hypertension. Eur Respir J 2007; 30: 922–7.
________________________________________________
2. Rossiiskoe meditsinskoe obshchestvo po arterial'noi gipertonii, RMOAG. Klinicheskie rekomendatsii "Legochnaia gipertenziia", 2016 g. KR158 (dostupno po ssylke: http://cr.rosminzdrav.ru/#!/recomend/136) (in Russian).
3. Chazova I.E., Martyniuk T.V. Pulmonary hypertension. Moscow, 2015; p. 17–108, 121–48, 189–227, 563–606 (in Russian).
4. Chazova I.E., Avdeev S.N., Tsareva N.A. et al. Klinicheskie rekomendatsii po diagnostike i lecheniiu legochnoi gipertonii.Therapeutic Archive. 2014; 86 (9): 4–23 (in Russian).
5. Martyniuk T.V. Pulmonary hypertension: diagnosis and treatment. Moscow, 2018; p. 148 (in Russian).
6. Galie N, Humbert M, Vachiery JL et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS). Eur Respir J 2015; 46 (4): 903–75.
7. Avdeev S.N. et al. Pulmonary hypertension: a guide for physicians. Moscow: GEOTAR-Media, 2019; p. 386–406 (in Russian).
8. Taran I, Martynyuk T, Chazova I et al. Initial Riociguat Monotherapy and Transition from Sildenafil to Riociguat in Patients with Idiopathic Pulmonary Arterial Hypertension: Influence on Right Heart Remodeling and Right Ventricular–Pulmonary Arterial Coupling. Lung (2018) 196: 745–53. https://doi.org/10.1007/ s00408-018-0160-4.
9. D’Alonzo GE, Barst RJ, Ayres SM et al. Survival in patients with pulmonary hypertension: results from a national prospective registry. Ann Intern Med 1991; 115: 343–9.
10. Chazova I.E., Arkhipova O.A., Martyniuk T.V. Legochnaia arterial'naia gipertenziia v Rossii: analiz shestiletnego nabliudeniia po dannym Natsional'nogo registra. Therapeutic Archive. 2019; 91 (1): 25–31 (in Russian).
11. Zhang M, Wang N, Zhai Z et al. Incidence and risk factors of chronic thromboembolic pulmonary hypertension after acute pulmonary embolism: a systematic review and meta-analysis of cohort studies. J Thorac Dis 2018; 10 (8): 4751–63. DOI: 10.21037/jtd.2018.07.106
12. Hoeper MM, Mayer E, Simonneau G, Rubin L J. Chronic thromboembolic pulmonary hypertension. Circulation 2006; 113: 2011–20.
13. Rubin LJ. Primary pulmonary hypertension. N Engl J Med 1997; 336: 111–7.
14. Yu Y, Yang L, Zhang Y et al. Incidence and risk factors of chronic thromboembolic pulmonary hypertension in patients with diagnosis of pulmonary embolism for the first time in real world. Clin Respir J 2018; 12: 2551–8. https://doi.org/10.1111/crj.12955
15. Belenkov Iu.N., Chazova I.E. Primary pulmonary hypertension. Moscow: Nolidzh, 1999 (in Russian).
16. Chazova I.E., Martyniuk T.V. Pulmonary hypertension. Moscow, Nolidzh, 2016; p. 141 (in Russian).
17. Nakonechnikov S.N., Zykov K.A., Martyniuk T.V. et al. The proinflammatory markers pattern of patients with different forms of pulmonary. Systemic Hypertension. 2010; 7 (3): 61–7 (in Russian).
18. Fedullo PF, Auger WR, Kerr KM et al. Chronic thromboembolic pulmonary hypertension. N Engl J Med 2001; 345: 1465–72.
19. Pengo V, Lensing AW, Prins MH et al. Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. N Engl J Med 2004; 350: 2257–64.
20. Rich S, Dantzker D, Ayres S et al. Primary pulmonary hypertension. A national prospective study. Ann Intern Med 1987; 107: 216–23.
21. Godfrey A, Cajigas H et al. A 55-Year-Old Woman With Pulmonary Hypertension, Worsening Dyspnea, and Chest Pain CHEST 2014; 145 (3): 642–5.
22. Martyniuk T.V. Idiopaticheskaia legochnaia gipertenziia: kliniko-patofiziologicheskie osobennosti i vozmozhnosti patogeneticheski obosnovannoi terapii. Avtoref. dis. … d-ra med. nauk. Moscow, 2013 (in Russian).
23. Chazova I.E., Arkhipova O.A., Valieva Z.S. et al. Pulmonary hypertension in Russia: The first results of the national register. Therapeutic Archive. 2014; 86 (9): 56–64 (in Russian).
24. Falletta C, Cascio C, Tuzzolino F et al. Accuracy of doppler echocardiography in measuring right-heart pressure in patients with pulmonary hypertension. Eur J Heart Fail 2010; 9: S33.
25. Martyniuk T.V., Chazova I.E. Pervye Rossiiskie rekomendatsii po diagnostike i lecheniiu legochnoi gipertenzii. Bolezni serdtsa i sosudov. 2007; 4: 45–51 (in Russian).
26. Kim NH, Delcroix M, Jenkins DP et al. Chronic Thromboembolic Pulmonary Hypertension. J Am Coll Cardiol 2013; 62 (Suppl.): 92–9.
27. Martyniuk T.V., Nakonechnikov S.N., Chazova I.E. Aktual'nye voprosy sovremennoi kombinirovannoi spetsificheskoi terapii legochnoi arterial'noi gipertenzii: za i protiv. Med. sovet. 2017; 5: 3–10 (in Russian).
28. Albania S, Biondia F, Stolfoa D et al. Chronic thromboembolic pulmonary hypertension (CTEPH): what do we know about it? A comprehensive review of the literature. J Cardiovasc Med 2019; 00 (00). DOI: 10.2459/JCM.0000000000000774
29. Konstantinides CV, Torbick A, Giancarlo Agnelli G et al. 2014 ESC Guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J 2014; 35: 3033–80.
30. Shmalts А.А., Gorbachevsky S.V. Nitrogen oxide biochemical pathway in pulmonary arterial hypertension therapy and REPLACE trial results. Systemic Hypertension. 2018; 15 (2): 72–6. DOI: 10.26442/2075-082X_2018.2.72-76 (in Russian).
31. Wilkens H, Lang I, Behr J et al. Chronic thromboembolic pulmonary hypertension (CTEPH): Updated Recommendations of the Cologne Consensus Conference. Int J Cardiol 2011; 154 (Suppl. 1): S54–S60.
32. Torbicki A, Perrier A, Konstantinides S et al. Guidelines on the diagnosis and management of acute pulmonary embolism: The Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). Eur Heart J 2008; 28: 2276–315.
33. Russian Medical Society for Arterial Hypertension. Clinical guidelines. Chronic thromboembolic pulmonary hypertension. Moscow, 2016. http://cr.rosminzdrav.ru/#!/recomend/137 (in Russian).
34. Wieteska M et al. Outcome of medically versus surgically treated patients with chronic thromboembolic pulmonary hypertension. Clin Appl Thromb/Hemost 2016; 22 (1): 92–9.
35. Martyniuk T.V., Dadacheva Z.Kh., Chazova I.E. Vozmozhnosti medikamentoznogo lecheniia khronicheskoi tromboembolicheskoi legochnoi gipertenzii. Spetsializirovannyi med. zhurnal. Aterotromboz. 2015; 1: 87–98 (in Russian).
36. McLaughlin W, Archer SL, Badesch DB et al.; ACCF/AHA.ACCF/AHA 2009 Expert Consensus Document on Pulmonary Hypertension. A Report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association. Developed in Collaboration With the American College of Chest Physicians, American Thoracic Society, Inc., and the Pulmonary Hypertension Association. Circulation 2009; 119 (16): 2250–94.
37. Ghofrani H-A et al. Riociguat for the Treatment of Pulmonary Arterial Hypertension. N Engl J Med 2013; 369: 330–40.
38. Rubin LJ et al. Riociguat for the treatment of pulmonary arterial hypertension: a long-term extension study (PATENT-2). Eur Respir J 2015; 45: 1211–3.
39. Ghofrani H-A et al. Predictors of long-term outcomes in patients treated with riociguat for pulmonary arterial hypertension: data from the PATENT-2 open-label, randomised, long-term extension trial. Lancet Respir Med 2016; 4: 361–71. http://dx.doi.org/10.1016/S2213-2600(16)30019-4
40. Halank M et al. Riociguat for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: Results from a phase II long-term extension study. Respir Med 2017; 128: 50–6.
41. Liu H et al. Efficacy and Safety of Pulmonary Arterial Hypertension-specific Therapy in Pulmonary Arterial Hypertension. A Meta-analysis of Randomized Controlled Trials. Chest 2016; 150 (2): 353–66.
42. Platonov D.Yu., Tsareva N.A., Avdeev S.N. Survival of patients with pulmonary arterial hypertension during therapy PAH-specific drugs. Systemic Hypertension. 2017; 14 (3): 58–64. DOI: 10.26442/2075-082X_14.3.58-64 (in Russian).
43. Hoeper MM et al. Targeted therapy of pulmonary arterial hypertension: Updated recommendations from the Cologne Consensus Conference 2018. Int J Cardiol 2018. https://doi.org/10.1016/j.ijcard.2018.08.082
44. Guha M. First-in-class guanylate cyclase stimulator approved for PAH. Nat Biotechnol 2013; 31: 1064.
45. Instruktsiia po meditsinskomu primeneniiu lekarstvennogo preparata Adempas. LP-002639 ot 05.10.2017 g. (dostupno po ssylke: https://grls.rosminzdrav.ru/GRLS.aspx?RegNumber=
&MnnR=%d0%a0%d0%b8%d0%be%d1%86%d0%b8%d0%b3%d1%83%d0%b0%d1%82&lf=&TradeNmR=&OwnerName=&MnfOrg=&MnfOrgCountry=&isfs=0&isND=-1®type=1%2c&pageSize=10&order=RegDate&orderType=desc&pageNum=1 (in Russian).
46. Olschewski H, Simonneau G, Galiè N et al. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 2002; 347 (5): 322–9.
47. Shmal'ts A.A., Gorbachevskii S.V. Riotsiguat i sildenafil v lechenii legochnoi gipertenzii: skhodstva i razlichiia. Pul'monologiia. 2016; 26 (1): 85–91 (in Russian).
48. Mershin K.V., Martyniuk T.V. Mesto medikamentoznoi terapii v lechenii khronicheskoi tromboembolicheskoi legochnoi gipertenzii. Evraziiskii kardiol. zhurnal. 2014; 1: 113–8 (in Russian).
49. Hoeper MM. Pharmacological therapy for patients with chronic thromboembolic pulmonary hypertension. Eur Respir Rev 2015; 24: 272–82.
50. Ghofrani HA, Hoeper MM, Halank M et al. Riociguat for chronic Thromboembolic pulmonary hypertension and pulmonary arterial hypertension: A phase II study. Eur Respir J 2010; 36: 792–9.
51. Ghofrani HA, D’Armini AM, Grimminger F et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. N Engl J Med 2013; 369: 319–29.
52. McLaughlin W, Jansa P, Jens E et al. Riociguat in patients with chronic thromboembolic pulmonary hypertension: results from an early access study. BMC Pulmonary Med 2017; 17: 216.
53. Simonneau G, D’Armini AM, Ghofrani H-A et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension: a long-term extension study (CHEST-2). Eur Respir J 2014; in press. DOI: 10.1183/09031936.00087114
54. Marra AM, Halank M, Benjamin N et al. Right ventricular size and function under riociguat in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension (the RIVER study). Respir Res 2018; 19: 258. https://doi.org/10.1186/s12931-018-0957-y
55. Hatano M et al. Significant Improvement Of Oxygen Saturation Of Peripheral Artery During Exercise In Patients With CTeph Treated With Riociguat. Am J Respir Crit Care Med 2016; 193: A5654. https://www.atsjournals.org/doi/abs/10.1164/ajrccm-conference.2016.193.1_MeetingAbstracts.A5654
56. Kambakamba A et al. Acute hemodynamic effects of riociguat in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. Eur Respir J 2018; 52 (Suppl. 62): PA3049. DOI: 10.1183/13993003.congress-2018.PA3049
57. Thenappan T et al. Survival in pulmonary arterial hypertension: a reappraisal of the NIH risk stratification equation. Eur Respir J 2010; 35: 1079–87.
58. European medicines agency. Committee for Medicinal Products for Human Use (CHMP) assessment report. EMA/CHMP/734750/2013. 23 January 2014. Adempas. Procedure No. EMEA/H/C/002737/0000.
59. Reichenberger F, Voswinckel R, Enke B et al. Long-term treatment with sildenafil in chronic thromboembolic pulmonary hypertension. Eur Respir J 2007; 30: 922–7.
Авторы
Д.Ю. Платонов*1,2, О.Э. Яковлева3, C.Н. Бельдиев1,2, Н.В. Ильин4, Т.Ю. Томская4, К.И. Иванов4
1 ФГБОУ ВО «Тверской государственный медицинский университет» Минздрава России, Тверь, Россия;
2 ГБУЗ ТО «Областная клиническая больница», Тверь, Россия;
3 ГБУЗ «Челябинский областной кардиологический диспансер», Челябинск, Россия;
4 ГАУ РС (Я) «Республиканская больница №1 – Национальный центр медицины», Якутск, Россия
*diplato64@mail.ru
1 ФГБОУ ВО «Тверской государственный медицинский университет» Минздрава России, Тверь, Россия;
2 ГБУЗ ТО «Областная клиническая больница», Тверь, Россия;
3 ГБУЗ «Челябинский областной кардиологический диспансер», Челябинск, Россия;
4 ГАУ РС (Я) «Республиканская больница №1 – Национальный центр медицины», Якутск, Россия
*diplato64@mail.ru
________________________________________________
1 Tver State Medical University, Tver, Russia;
2 Regional Clinical Hospital, Tver, Russia;
3 Chelyabinsk Regional Cardiological Dispensary, Chelyabinsk, Russia;
4 Republican Hospital №1 – National Medical Center, Iakutsk, Russia
*diplato64@mail.ru
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.